StonvexLoading…
StonvexStonvexStonvexWhat you need to know right now
This is an algorithmic assessment of current technical conditions, not investment advice. Past performance does not guarantee future results.
Real-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →6-factor scoring with sector-relative rank. Updated daily.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
Next report date, year-over-year trend, and recent quarter history.
5-factor analysis: Valuation, Growth, Profitability, Momentum, Financial Health.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
Past 1 reported quarters: EPS surprise vs estimate and the day-after-release stock reaction. Past performance does not predict future moves.
Sources: Finnhub earnings calendar + Polygon daily aggregates. Reaction direction can diverge from EPS surprise (guidance, macro, or sector flow can dominate the next-day print).
Earnings (▲ beat / ▼ miss) and ex-dividend dates plotted on the price line. Educational — proximity does not establish causation.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-12 | $79.31 | $79.50 | +0.24% | 0.6M |
| 05-13 | $78.16 | $80.88 | +3.48% | 0.3M |
| 05-14 | $80.70 | $79.58 | -1.39% | 0.2M |
| 05-15 | $79.28 | $78.01 | -1.60% | 0.3M |
| 05-18 | $77.88 | $78.23 | +0.45% | 0.0M |
These are published opinions from external sell-side analysts — not Stonvex recommendations. Ratings may change without notice, may conflict with each other, and may be wrong. Not investment advice.
Consensus aggregated from publicly disclosed sell-side analyst ratings. Stonvex is not a registered investment advisor and does not endorse any of the ratings shown. Past analyst ratings do not predict future price movements.
Each factor shows ANIP's percentile within the scored universe — observational ranking, not a recommendation.
| Metric | Q3 2026 (Est.) Expected 2026-08-06 | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|---|
Revenue | $268.67M | $237.46M | $883.37M | $636.31M | $408.49M |
Operating Income | Not available | $38.89M | $111.09M | $76.33M | $40.09M |
Net Income | Not available | $29.49M | $78.34M | $50.85M | $24.23M |
EPS (Diluted) | $2.04 | $1.28 | $3.32 | $2.15 | $1.05 |
Total Assets | Not available | $1.42B | $1.44B | $1.41B | $1.34B |
Total Liabilities | Not available | $859.67M | $899.65M | $902.34M | $881.39M |
Cash & Equivalents | Not available | $311.18M | $285.58M | $262.61M | $217.80M |
Free Cash Flow OCF − CapEx | Not available | $52.30M | $171.39M | $142.27M | $104.31M |
Shares Outstanding | Not available | 21.54M | 22.49M | 20.91M | 20.18M |
ANI Pharmaceuticals Inc is a diversified biopharmaceutical company. It is focused on developing, manufacturing, and commercializing therapeutics through its Rare Disease business, which markets novel products in the areas of ophthalmology, rheumatology, nephrology, neurology, and pulmonology; and through its Generics and Brands businesses. The firm's product portfolio comprises Purified Cortrophin Gel, ILUVIEN, and YUTIQ (fluocinolone acetonide intravitreal implant), among others. Additionally, its Generics portfolio includes several products with a wide variety of indications. The company has two operating segments: Rare Disease and Brands, which derive maximum revenue, and Generics and Other. Geographically, it generates maximum revenue from the United States, followed by other markets.
Aggregated from Polygon's per-article sentiment classifications. Educational — sentiment is descriptive, not predictive.